Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume – Here’s What Happened

Elekta AB (OTCMKTS:EKTAY) saw unusually-high trading volume on Monday . 3,119 shares were traded during mid-day trading, an increase of 14% from the previous session’s volume of 2,725 shares.The stock last traded at $4.94 and had previously closed at $4.7704.

Analysts Set New Price Targets

Separately, Zacks Research lowered Elekta from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Elekta Price Performance

The stock has a market capitalization of $1.82 billion, a PE ratio of -30.84 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.87 and a quick ratio of 0.68. The stock’s fifty day moving average is $5.39 and its 200-day moving average is $5.88.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $521.00 million during the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. As a group, equities analysts predict that Elekta AB will post 0.43 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.